Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Research

• Publication date

  2001-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 11431348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells

  2004cited by this paper
• Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C

  2004cited by this paper
• Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.

  2001cited by this paper
• Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.

  2001cited by this paper
• S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.

  2001cited by this paper
• Serine/threonine protein kinases and apoptosis.

  2000cited by this paper
• The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01*

  2000influential reference
• Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes.

  2000cited by this paper
• Potentiation of 1-β- d-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) ∗ ∗ Portions of this work have been reported in preliminary form at the Meeting for the American Ass

  2000cited by this paper
• Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

  2000cited by this paper
• Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases.

  2000cited by this paper
• Apaf-1 Oligomerizes into Biologically Active ∼700-kDa and Inactive ∼1.4-MDa Apoptosome Complexes*

  2000cited by this paper
• Caffeine Abolishes the Mammalian G2/M DNA Damage Checkpoint by Inhibiting Ataxia-Telangiectasia-mutated Kinase Activity*

  2000cited by this paper
• The Pyridinyl Imidazole Inhibitor SB203580 Blocks Phosphoinositide-dependent Protein Kinase Activity, Protein Kinase B Phosphorylation, and Retinoblastoma Hyperphosphorylation in Interleukin-2-stimulated T Cells Independently of p38 Mitogen-activated Protein Kinase*

  2000cited by this paper
• Structural and biochemical basis of apoptotic activation by Smac/DIABLO

  2000cited by this paper
• Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).

  2000cited by this paper
• The MAPK/ERK Cascade Targets Both Elk-1 and cAMP Response Element-Binding Protein to Control Long-Term Potentiation-Dependent Gene Expression in the Dentate Gyrus In Vivo

  2000cited by this paper
• Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras

  2000cited by this paper
• Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.

  2000cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors.

  2000cited by this paper
• Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin*

  2000cited by this paper
• Mitochondrial Regulation of Cell Death: Mitochondria Are Essential for Procaspase 3-p21 Complex Formation To Resist Fas-Mediated Cell Death

  1999cited by this paper
• Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.

  1999cited by this paper
• Diverse functions of JNK signaling and c-Jun in stress response and apoptosis

  1999cited by this paper
• Caffeine inhibits the checkpoint kinase ATM.

  1999cited by this paper
• Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01

  1999cited by this paper
• Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.

  1999cited by this paper
• UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent

  1999cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper
• Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons.

  1999cited by this paper
• The stress-activated protein kinase pathways

  1999influential reference
• Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.

  1999cited by this paper
• Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.

  1999cited by this paper
• Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis*

  1999cited by this paper
• Collapse of the inner mitochondrial transmembrane potential is not required for apoptosis of HL60 cells.

  1999cited by this paper
• C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding.

  1998cited by this paper
• SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis.

  1998cited by this paper
• Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD‐specific caspase activation and independently of mitochondrial transmembrane depolarization

  1998influential reference
• Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase*

  1998cited by this paper
• Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.

  1998influential reference
• Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.

  1998cited by this paper
• Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C.

  1998cited by this paper
• Regulation of cell death protease caspase-9 by phosphorylation.

  1998cited by this paper
• Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.

  1997cited by this paper
• Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.

  1997cited by this paper
• Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.

  1997cited by this paper
• Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway.

  1997cited by this paper
• Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked

  1997cited by this paper
• Cytochrome c-dependent and -independent Induction of Apoptosis in Multiple Myeloma Cells*

  1997cited by this paper
• Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.

  1996cited by this paper
• Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis

  1996cited by this paper
• Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.

  1996cited by this paper
• Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents

  1996cited by this paper
• Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.

  1995cited by this paper
• The MAPK signaling cascade

  1995cited by this paper
• Cell cycle and apoptosis: Common pathways to life and death

  1995cited by this paper
• Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage.

  1995cited by this paper
• Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis

  1995cited by this paper
• A synthetic inhibitor of the mitogen-activated protein kinase cascade.

  1995influential reference
• UCN‐01, an anti‐tumor drug, is a selective inhibitor of the conventional PKC subfamily

  1995influential reference
• Inactivation of Bcl-2 by phosphorylation.

  1995cited by this paper
• Induction of a common pathway of apoptosis by staurosporine.

  1994influential reference
• Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.

  1994cited by this paper
• Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.

  1994cited by this paper
• Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays.

  1993cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Molecular pharmacology of multitarget cyclin-dependent kinase inhibitors in human colorectal carcinoma cells

  2023cites this paper
• Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy

  2022cites this paper
• Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

  2021cites this paper
• Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

  2020cites this paper
• Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance

  2020cites this paper
• Epigenetic based synthetic lethal strategies in human cancers

  2020cites this paper
• Synthetic lethality on drug discovery: an update on cancer therapy

  2020cites this paper
• The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.

  2019cites this paper
• Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer

  2019cites this paper
• Targeting dormant ovarian cancer cells in vitro and in an in vivo model of platinum resistance

  2019cites this paper
• Cell cycle regulation and hematologic malignancies

  2019cites this paper
• Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer

  2018cites this paper
• Mechanistic considerations in chemotherapeutic activity of caffeine.

  2018cites this paper
• Caffeine induces metformin anticancer effect on fibrosarcoma in hamsters.

  2018cites this paper
• Functional Signature Ontology-Based Identification and Validation of Novel Therapeutic Targets and Natural Products for the Treatment of Cancer

  2018cites this paper
• Role of Apoptosis and Mitochondrial Dysfunction in the Treatment of Leukemia Types

  2018cites this paper
• ATR/CHK1 inhibitors and cancer therapy.

  2017cites this paper
• Development of Visible-Wavelength MALDI Cell Mass Spectrometry for High-Efficiency Single-Cell Analysis.

  2016cites this paper
• Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

  2016cites this paper
• القای مرگ سلولی و کاهش تکثیر در سلول لوسمی پرومیلوسیتیک حاد NB4 توسط کافئین

  2016cites this paper
• Transport stress induces apoptosis in rat myocardial tissue via activation of the mitogen-activated protein kinase signaling pathways

  2016cites this paper
• Dual roles of ERK1/2 in cellular senescence induced by excess thymidine in HeLa cells.

  2016cites this paper
• Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK.

  2016cites this paper
• Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

  2015cites this paper
• Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736

  2015cites this paper
• Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.

  2015cites this paper
• Rational Combinations of Targeted Agents in AML

  2015cites this paper
• Timosaponin AIII mediates caspase activation and induces apoptosis through JNK1/2 pathway in human promyelocytic leukemia cells

  2015cites this paper
• WEE1 Kinase As a Target for Cancer Therapy.

  2015cites this paper
• Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.

  2015cites this paper
• Maternal caffeine exposure impairs insulin secretion by pancreatic β‐cells and increases the risk of type II diabetes mellitus in offspring

  2014cites this paper
• CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.

  2014cites this paper
• Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors

  2014cites this paper
• THE EFFECTS OF CAFFEINE ON CYTOSKELETON IN CHO AA8 CELL LINE

  2014cites this paper
• Drink your prevention: beverages with cancer preventive phytochemicals.

  2014cites this paper
• Caffeine induces cytoskeletal changes and cell death in H1299 cells

  2014cites this paper
• Two Birds with a Stone: Molecular Cancer Therapy Targeting Signal Transduction and DNA Repair Pathways

  2013cites this paper
• PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

  2013cites this paper
• Induction of death of leukemia cells by TW-74, a novel derivative of chloro-naphthoquinone.

  2013cites this paper
• Saikosaponin D disrupts platelet-derived growth factor-β receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity.

  2013cites this paper
• Targeting the Cell Cycle for Cancer Treatment and Neuroprotection

  2013cites this paper
• therapeutic targets in human leukemia A selective sphingosine kinase 1 inhibitor integrates multiple molecular

  2013cites this paper
• Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

  2013cites this paper
• The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

  2013cites this paper
• Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells

  2013cites this paper
• Chemical Therapeutics The Novel Chk 1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

  2013cites this paper
• farnesylation and activation lethality in human leukemia and myeloma cells by disrupting Ras Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01)

  2013cites this paper
• Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors □ S

  2012cites this paper
• Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies

  2012cites this paper
• Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors

  2012cites this paper
• Checkpoint Kinase and Wee1 Inhibitors as Anticancer Therapeutics

  2012cites this paper
• Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?

  2012cites this paper
• Enhancing CHK1 inhibitor lethality in glioblastoma

  2012cites this paper
• Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance

  2011cites this paper
• Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma

  2011cites this paper
• Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.

  2011cites this paper
• Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death

  2011cites this paper
• Synthetic lethality: exploiting the addiction of cancer to DNA repair.

  2011cites this paper
• Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim

  2011cites this paper
• PARP Inhibitors Synergize With Loss of Checkpoint Control to Kill Mammary Carcinoma Cells

  2011cites this paper
• TITLE: PARP Inhibitors Synergize With Loss of Checkpoint Control to Kill Mammary Carcinoma Cells

  2011cites this paper
• Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

  2011cites this paper
• Methods to study cancer therapeutic drugs that target cell cycle checkpoints.

  2011cites this paper
• CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

  2011cites this paper
• Cytokinetically quiescent ( G 0 / G 1 ) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk 1 and MEK 1 / 2

  2011cites this paper
• Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells

  2010cites this paper
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cites this paper
• The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.

  2010cites this paper
• Correction to “Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells”

  2010cites this paper
• CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells

  2010cites this paper
• PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01

  2010cites this paper
• Molecular Cancer apeutics apeutic Discovery A Induction by FoxO 3 a Mediates the Anticancer ivities of the Broad-Range Kinase Ther bitor UCN-01

  2010cites this paper
• Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

  2010cites this paper
• The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.

  2009cites this paper
• Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics

  2009cites this paper
• THE SMALL MOLECULE BCL-2 INHIBITOR HA14-1 POTENTIATES THE LETHALITY OF A REGIMEN COMBINING MEK1/2 AND CHK1 INHIBITORS IN MULTIPLE MYELOMA CELLS

  2009cites this paper
• The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy

  2009cites this paper
• Use of liposomes as drug delivery vehicles for treatment of melanoma

  2009cites this paper
• All-trans retinoic acid promotes neural lineage entry by pluripotent embryonic stem cells via multiple pathways

  2009influential citation
• The BH 3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI 3 K / Akt and MEK / ERK 1 / 2 pathways

  2009cites this paper
• DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.

  2009cites this paper
• Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

  2008cites this paper
• A prenylation inhibitor (sodium phenylacetate) differently affects MCF-7 cell death when ras is overexpressed, partly involving P42/44, JNK and P38 kinase activations.

  2008cites this paper
• Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

  2008cites this paper
• A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.

  2008cites this paper
• Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.

  2008cites this paper
• Treatment of melanoma and breast cancer with genetic based liposomal drug formulations

  2008influential citation
• CDK Inhibitors in Multiple Myeloma

  2008cites this paper
• Chapter 22 CDK Inhibitors in Multiple Myeloma

  2008cites this paper
• Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

  2008cites this paper
• Resistance/Signaling Pathways

  2007cites this paper
• Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.

  2007cites this paper
• Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

  2007cites this paper
• The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress

  2007influential citation
• Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.

  2007cites this paper
• Are MAP Kinases Drug Targets? Yes, but Difficult Ones

  2007cites this paper
• PD184352 releases the regular hypoxic reversible DNA replication arrest in T24 cells.

  2007cites this paper
• PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.

  2007cites this paper
• Emerging Therapeutics for AML

  2007cites this paper
• Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB.

  2007cites this paper